Adjuvantix

ADX40 - Mode of Action

ADX40 is rationally designed adjuvant that acts as a potent stimulator of the immune system. Vaccine antigens are conjugated to the ADX40 which acts as a receptor agonist by binding to key complementary receptors on antigen presenting cells and B cells.

This selective receptor binding causes specific immune enhancement to linked vaccine antigens. The result is an enhanced immune response - specific to the vaccine.

In immunocompromised individuals such as cancer patients, ADX40 could act as a surrogate or replacement stimulatory/co-stimulatory signal which could overcome the immune tolerance that would otherwise be seen against vaccines. Improving immune responsiveness to co-delivered vaccines could be possible in cancer patients receiving ADX40 as an adjuvant.

ADX40 Target Product Profile:

• ADX40 has potential to be conjugated to a wide variety of antigens with different physical characteristics including synthetic peptides, recombinant proteins (including monoclonal antibodies) or polysaccharides.

• ADX40 could be applied to antigens from infectious pathogens, polyvalent and antigen-specific cancer vaccines.

• ADX40 can be administered as a single prime dose via the i.m. or s.c. routes and may be amenable to boosting

• Humanisation will minimise anti-vector immunity and minimise any drop in efficacy or adverse events on repeat clinical immunisation.

• Comparatively low doses are effective, which should lower the cost of goods.